The immunoregulatory activity of a nonmammalian interleukin 2 (IL-2), chicken IL-2 (chIL-2), was investigated using a DNA vaccine against infectious bursal disease virus (IBDV) as a model. Coadministration of a plasmid encoding the VP2 gene of IBDV (pCI-VP2) and a plasmid encoding chicken IL-2 gene (pCI-chIL-2) enhances bursal protection against both the homologous IBDV strain ZJ2000 and the heterologous strain BC6/85 compared to administration of pCI-VP2 alone. Vaccination with pCI-VP2 alone induces low bursal protection against ZJ2000 and only protects chickens from clinical outbreaks and mortality, but not from bursal damage caused by BC6/85. Coadministration of the plasmid encoding the polyprotein gene of IBDV (pCI-VP2/4/3) and pCI-chIL-2 provides complete protection (15/15) against ZJ2000 and satisfactory protection (13/15) against BC6/85. In contrast, only 10 out of 15 chickens and 6 out of 15 chickens were protected against ZJ2000 and BC6/85, respectively, using the pCI-VP2/4/3 vaccination alone. A significant increase in the IBDV-specific neutralizing antibody response was also observed in chickens that received pCI-VP2/4/3 plus pCI-chIL-2 as compared with those that received the pCI-VP2/4/3 vaccination alone. By administrating different amounts of plasmid DNA, we confirmed that the pCI-chIL-2, but not the backbone plasmid pCI, contributes to increased immunoprotection of DNA vaccine against IBDV. These results strongly indicate that the efficacy of avian DNA vaccine can be modulated by co-administration of a plasmid encoding chIL-2.
Introduction
Infectious bursal disease virus (IBDV) is the causative agent of a highly immunosuppressive disease in young chickens. IBDV is a member of the Birnaviridae family. Its genome consists of two segments of double-stranded RNA. The smaller segment B (approximately 2.9 kb) encodes VP1, a 90-kDa multifunctional protein with polymerase and capping enzyme activities (Lombardo et al., 1999) . The larger segment A (approximately 3.3 kb) contains two partially overlapping open reading frames (ORFs). The first ORF encodes the nonstructural protein VP5 (17 kDa), which has recently been shown to be dispensable for viral replication, but important for viral pathogenesis (Mundt et al., 1997; Yao and Vakharia, 2001 ). The second ORF encodes a 110-kDa polyprotein (VP2/4/3) that is cleaved by autoproteolysis to form the viral proteins pVP2 (48 kDa), VP3 (32 kDa), and VP4 (28 kDa). During virus maturation, the precursor pVP2 is further processed into mature VP2 (40 kDa) (Chevalier et al., 2002) . The viral protease VP4 is responsible for self-processing of the polyprotein (Sánchez and Rodriguez, 1999) . VP3 contains group-specific anti-gens, and it interacts with VP1 and viral dsRNA (Tacken et al., 2002) . VP2 is the major host-protective immunogen responsible for induction of neutralizing antibodies (Fahey et al., 1989) . Vaccination with VP2 or polyprotein subunit vaccines was able to induce protection against IBDV (Darteil et al., 1995; Fahey et al., 1989; Shaw and Davison, 2000; Tsukamoto et al., 1999 Tsukamoto et al., , 2000 . Complete protection was conferred by vaccination with IBDV antigens expressed by the baculovirus (Pitcovski et al., 1996; Vakharia et al., 1994) , avian herpesvirus vector (Tsukamoto et al., 2002) , and Pichia pastoris yeast (Pitcovski et al., 2003) .
DNA vaccines induce both the cellular and humoral immune responses to produce long-lasting immunity against infectious diseases. Plasmids encoding antigens of IBDV have been shown to be capable of inducing protective immune responses in chickens (Chang et al., 2001 (Chang et al., , 2003 Fodor et al., 1999; Heckert et al., 2002) . However, the efficacy of DNA vaccine is lower than that of commercial inactivated and attenuated IBDV vaccines (Fodor et al., 1999) . Only 4 out of 20 chickens were protected from virulent IBDV challenge even after several inoculations of large amounts of plasmids expressing the polyprotein gene of IBDV (Fodor et al., 1999) . Furthermore, we have recently shown that the source of the target genes (from different IBDV strains), the eukaryotic expression vector, the adjuvant, the delivery route, and the dosage play a role of varying degree in influencing the efficacy of the DNA vaccine against IBDV (Li et al., 2003) .
Chemical adjuvants such as liposome and dimethylsulfoxide (DMSO) have been shown to enhance the efficacy of DNA vaccination (Heckert et al., 2002) . However, these adjuvants are expensive and difficult to use in the poultry industry. Therefore, the generation of a more effective and economical adjuvant is required. It has been demonstrated that the efficacy of DNA vaccines can be modulated by codelivery of various cytokine genes (Moore et al., 2002) . Interleukin 2 (IL-2) is perhaps the most extensively studied of all cytokine adjuvants. Several studies have shown that the immune responses to DNA vaccines can be enhanced dramatically by co-administration of plasmids encoding the mammalian IL-2 gene. Examples of this phenomena have been found for vaccination against bovine herpesvirus 1 virus (Kuhnle et al., 1996) , hepatitis C virus (Geissler et al., 1997) , hepatitis B virus (Chow et al., 1997 (Chow et al., , 1998 , bovine viral diarrhea virus (Nobiron et al., 2001) , HIV (Moore et al., 2002) , foot-and-mouth disease (Wong et al., 2002) , and measles virus (Premenko-Lanier et al., 2003) .
A chicken cytokine with T-cell proliferative activity was cloned using expression library screening (Sundick and Gill-Dixon, 1997) . Sequence analysis revealed that this cytokine has characteristics similar to both mammalian IL-2 and IL-15. Kaiser and Mariani (1999) identified this cytokine as chIL-2, but not chicken IL-15, because the genomic structure, promoter sequence, exon/intron structure, and synteny of the genetic location of this chicken cytokine are more similar to those of mammalian IL-2 than of IL-15. Recombinant chIL-2 produced in prokaryotic and eukaryotic expression systems induces proliferation of chicken splenocytes and thymocytes in vitro (Stepaniak et al., 1999 ). Yet, the immunoregulatory effects of chIL-2 on T cells, B cells, natural killer cells, and lymphokineactivated killer cells in vivo, as well as in vitro, and its feasibility as an adjuvant for avian vaccines are poorly understood. To date, only one study has tested the use of chIL-2 as a DNA vaccine adjuvant, and, unfortunately, it did not have significant effect on the efficacy of DNA vaccination against Eimeria (Min et al., 2001) .
A chIL-2 cDNA has been cloned from Concanavalin A (Con A) stimulated spleen T lymphocytes in our laboratory. Using the highly immunosuppressive avian pathogen IBDV as a model, we have found that chIL-2 can be successfully used as a strong immunoenhancer of DNA vaccination. Enhancement of the protection against both homologous and heterologous strains of virulent IBDV was induced by co-administration of an IBDV DNA vaccine and a plasmid encoding chIL-2. Additionally, there was a significant improvement in the IBDV-specific antibody response. The discovery of an immunoenhancer function of chIL-2 reveals a new potential approach to the development of a natural adjuvant for avian DNA vaccines.
Results

Characterization of the Xiaoshan chicken interleukin 2 gene
Based on the chIL-2 sequence published by Sundick and Gill-Dixon (1997) , two primers were designed that spanned the coding region of chIL-2. Isolation of spleen lymphocytes from Xiaoshan chickens, activation by ConA, extraction of total RNA, followed by RT-PCR resulted in the synthesis of a 737-bp DNA fragment (data not shown). The chIL-2 ORF was inserted into the pCI vector under control of the CMV promoter. The sequence of the Xiaoshan chIL-2 gene is available in GenBank at accession number AF321056. The full-length chIL-2 cDNA is 737 bp, encoding a 143 amino acid precursor. One to five amino acid differences were identified in a comparison of our sequence with the three previously published chIL-2 sequences. Xiaoshan chIL-2 shares 58.4% homology with duck IL-2, 69.4% homology with turkey IL-2, and 21.2-29.4% homology with mammalian IL-2. The predicted Xiaoshan chIL-2 protein has a leader sequence composed of 22 amino acids and four conserved cysteines that allow the formation of two intrachain disulfide bonds. In comparison, mammalian IL-2 has only three cysteine residues that allow for only one intrachain disulfide bond. There are four heptad repeats with hydrophobic amino acids at positions 1 and 4, which are presumably forming amphipathic alpha-helices. These regions are equivalent to mammalian IL-2 helices A, B, C, and D. In mammalian IL-2, several of the residues important for binding to IL-2 receptors are also found in chIL-2 at positions 40(D), 65(Y), 82(E), 108(N), and 142(Q). Phylogenetic analysis indicates that Xiaoshan chIL-2 is most closely related to other avian IL-2, including those of turkey, duck, and three other chicken breeds. It appears to have an evolutionary relationship with mammalian IL-2, but it is distinct from the IL-15 family (Fig. 1) . Recombinant chIL-2 expressed in CEFs was biologically active as quantitated using a T cell proliferation assay (data not shown).
Enhanced immunoprotection of DNA vaccine against homologous virulent IBDV strain ZJ2000 by co-administration of chIL-2
At day 4 postchallenge, all of the chickens were euthanized. As shown in Table 1 , both the plasmid encoding VP2 (pCI-VP2) and the plasmid encoding the polyprotein gene (pCI-VP2/4/3) provided partial bursal protection against the homologous virulent ZJ2000. However, the efficacy of the DNA vaccine using polyprotein as the target gene was much higher than that of the DNA vaccine using the VP2 gene. Ten out of fifteen chickens (10/15) in the pCI-VP2/4/3 group were protected from virus challenge. In contrast, only 3 out of 15 chickens (3/15) in the pCI-VP2 group were protected from virus challenge.
Co-administration of chIL-2 enhanced the protective immune response of both the VP2/4/3 and the VP2-based DNA vaccines. Co-administration of pCI-VP2/4/3 and pCIchIL-2 provided complete protection (15/15) against the homologous virulent ZJ2000 strain, while vaccination with pCI-VP2/4/3 alone provided partial protection (only 10 out of 15 chickens were protected). Ten out of fifteen chickens (10/15) were protected when the pCI-VP2 plus pCI-chIL-2 DNA vaccine was used. However, only 3 out of 15 chickens (3/15) were protected when the pCI-VP2 DNA vaccine was used alone. The bursa lesion scores of the chickens in coadministration groups were significantly reduced as compared to DNA vaccination alone ( P b 0.05). The bursa/BW and spleen/BW ratios of the chickens in co-administration group had no significant difference from those of the normal control ( P N 0.05).
The chickens vaccinated with pCI, as well as those unvaccinated but challenged, were not protected from virus challenge and 4 out of 15 chickens died by day 4 postchallenge in both groups. These chickens showed the typical clinical signs of IBDV, which included severe gross bursal lesions characterized by inflammation, pale-color, edema and point bleeding, and had significantly larger bursas and spleens than normal chickens ( P b 0.05). All of the chickens vaccinated with pCI-chIL-2 also showed gross bursal lesions. Although the bursal lesion scores (2.6 F 0.51) from pCI-chIL-2 group were slightly less than those of the pCI and unvaccinated challenge control groups (3 F 0), there is no statistically significant difference among them ( P N 0.05). In addition, none of the pCI-chIL-2 vaccinated chickens had died by day 4 postchallenge.
Enhanced cross-protection of DNA vaccine against heterologous virulent BC6/85 by co-administration of chIL-2
The antigenic relationship between the IBDV strain used to vaccinate and the IBDV strain used to challenge is very important in evaluating the efficacy of the vaccine. Although DNA vaccination (pCI-VP2/4/3 plus pCI-chIL-2) provided complete protection against the homologous strain ZJ2000, protection against heterologous IBDV strains needs to be examined. For this purpose, another virulent strain, BC6/85, was chosen as the challenge virus. BC6/85 is widely used in the evaluation of the efficacy of IBDV vaccines in China.
As shown in Table 2 , chickens immunized with DNA encoding ZJ2000 VP2 (pCI-VP2) were not protected from bursal damage by heterologous virulent BC6/85, even when a high DNA dosage (200 Ag) and a boosting vaccination was used for the immunization. In the pCI-VP2 group, some of chickens did not have gross bursal lesions, but the final histopathological examination showed that all of the bursa from this group had histopathological lesions. However, none of the chickens displayed clinical signs of IBDV and none of the chickens died after challenge with BC6/85. Thus, pCI-VP2 vaccination alone only protected chickens from clinical outbreaks and mortality, but not from bursal damage. Similar to the results of experiment 1, chickens immunized with plasmid DNA encoding the VP2/4/3 (pCI-VP2/4/3) displayed partial protection from bursal damage by the heterologous strain BC6/85. However, only 6 out of 15 chickens (6/15) were protected, which was less than the number protected against the homologous ZJ2000 strain (10/15).
Co-administration of pCI-chIL-2 significantly enhanced the efficacy of both the pCI-VP2/4/3 and pCI-VP2 DNA vaccines against virulent strain BC6/85 ( P b 0.05). Coadministration of pCI-VP2 and pCI-chIL-2 was able to induce bursal protection against BC6/85. None of the chickens challenged with BC6/85 had clinical symptoms of IBDV, and 7 out of 15 chickens (7/15) were protected from challenge at the bursal pathological level. However, none of bursa were protected when only the pCI-VP2 vaccination was used. The bursa lesion scores were significantly reduced by co-delivery with pCI-chIL-2 ( P b 0.05). Thirteen out of fifteen chickens (13/15) in the pCI-VP2/4/3 plus pCI-chIL-2 group were protected from BC6/ 85 challenge, which was much higher than the number of chickens protected in the pCI-VP2/4/3 group (6/15). The bursa lesion scores in pCI-VP2/4/3 plus pCI-chIL-2 group were significantly less than those of pCI-VP2/4/3 group ( P b 0.05). The bursa/BW and spleen/BW ratios of chickens vaccinated with pCI-VP2/4/3 and pCI-chIL-2 were not significantly different from those of the unvaccinated yet unchallenged controls ( P N 0.05). In contrast, chickens vaccinated with control pCI and those that were unvaccinated were not protected from BC6/85 challenge and had significantly larger bursas and spleens ( P b 0.05). These chickens showed the typical clinical signs of IBDV and had severe bursal lesions as mentioned previously. At day 4 postchallenge, 4 out of 15 (4/15) and 5 out of 15 chickens (5/15) died in the pCI control and challenge control groups, respectively. Chickens vaccinated with pCI-chIL-2 alone were not protected and one chicken in this group had died by day 4 postchallenge. The bursal lesion score in pCI-chIL-2 group was 2.73 F 0.46, which a Chickens were inoculated with 200 Ag of each DNA at 2 weeks of age and boosted 2 weeks later. All of the chickens were challenged via eye drop with 2 Â 10 4 embryo infective dose (EID 50 ) per milliliter of virulent IBDV strain ZJ2000 at week 4 postboosting. VP2/4/3 represents the polyprotein gene. b Bursal lesion scores were based on the system described by Shaw and Davison (2000) with some modification. Bursal lesion scores were shown as the mean F standard deviation for 15 chickens. c Values show the averages for 15 chickens. Average organ/BW = average organ in grams/total body weight in grams. Values within a column followed by different lowercase letters (a or b) are significantly different from the normal control ( P b 0.05). d Number of dead chickens at 4 day postchallenge. e The protection rate for each challenge group was initially calculated based on gross bursal lesions and further confirmed by bursa histopathological examination. f Number of chickens absent of antigen detection. g Number of chickens with NA (neutralizing antibody) response at week 4 postboosting vaccination.
is slightly less than those of the pCI and unvaccinated challenge controls (3.0 F 0), yet they were not significantly different ( P N 0.05).
Effect of different DNA concentration on immunoprotection of DNA vaccine
As shown in experiments 1 and 2, immunoprotection induced by DNA vaccination against IBDV can be improved by co-delivery of a plasmid encoding chicken IL-2. However, the concentration of plasmid DNA used in these experiments was not consistent. Co-injection of the pCI-chIL-2 plasmid resulted in delivery of twice the amount of DNA because empty backbone plasmid pCI was not coinjected when the pCI-VP2 or pCI-VP2/4/3 plasmid was tested. One might argue that some portion of the increased protection in the groups receiving pCI-chIL-2 is nonspecific due to the extra DNA administrated. To address this question, we repeated experiment 2 but controlled the amount of DNA in immunization by co-administrating backbone plasmid pCI. Table 3 shows the effect of DNA concentration on the efficacy of the DNA vaccine. Similar to our previous finding, none of the chickens (0/12) were protected at the bursal pathological level in the group that received 200 Ag pCI-VP2 and 4 out of 12 chickens (4/12) were protected in the group that received 200 Ag pCI-VP2/ 4/3. None of the chickens (0/12) were protected in the group that received 200 Ag each of pCI-VP2 and pCI. Only 5 out of 12 chickens (5/12) were protected in the group that received 200 Ag each of pCI-VP2/4/3 and pCI. Therefore, backbone plasmid pCI does not significantly enhance the immunoprotection of either the pCI-VP2 or the pCI-VP2/4/ 3-based DNA vaccines ( P N 0.05). Also, co-delivery with pCI does not significantly reduce the bursa lesion scores caused by virulent IBDV ( P N 0.05). However, co-injection with 200 Ag pCI-chIL-2 significantly enhanced the immunoprotection of the pCI-VP2 and pCI-VP2/4/3 DNA vaccines ( P b 0.05). Five out of twelve chickens (5/12) were protected in the group that received 200 Ag each of pCI-VP2 and pCI-chIL-2 and 10 out of 12 chickens (10/12) were protected in the group that received 200 Ag each of pCI-VP2/4/3 and pCI-chIL-2. Similar to our previous findings, co-delivery of pCI-chIL-2 significantly reduced the bursa lesion scores ( P b 0.05). As for the controls, none of chicken vaccinated with 200 Ag pCI-chIL-2, 200 Ag each of pCI-chIL-2 and pCI, and 400 Ag pCI were protected against challenge with IBDV. Therefore, the increased immunoprotection is indeed due to the co-injection of plasmid encoding chIL-2, and not due to the increased amount of DNA (pCI) administrated. Co-injection with backbone plasmid pCI does not significantly improve the efficacy of DNA vaccination ( P N 0.05).
Reduction of IBDV antigen replication in bursa of Fabricius by co-administration of chIL-2
To detect whether DNA vaccination can prevent virus replication in bursa of Fabricius, bursa section from each group was subjected to examination of the presence of IBDV antigens in bursa of Fabricius by an immunofluorescence assay at day 4 after challenge with virulent IBDV. As shown in Tables 1-3, co-administration of either pCI-VP2/4/3 or pCI-VP2 with pCI-chIL-2 reduced the IBDV antigen positive ratio as compared to ratios seen when the pCI-VP2/4/3 or pCI-VP2 vaccination alone was used. This indicates that chIL-2 was able to enhance the ability of the DNA vaccine to prevent IBDV replication in the bursa postchallenge. However, co-administration of either pCI-VP2/4/3 or pCI-VP2 with backbone plasmid pCI did not reduce the IBDV antigen-positive ratio as compared to DNA vaccination alone (Table 3 ). All of the chickens in the pCIchIL-2, pCI, and challenge controls were positive for antigen. No antigen was detected in any of the chickens in the normal control group.
Enhanced antibody response of DNA vaccine by co-administration of pCI-chIL-2 Although VP2 is the major host-protective antigen responsible for the induction of neutralizing antibodies, DNA encoding the VP2 gene was not efficient at eliciting an antibody response. Even at week 4 postboosting vaccination, only 9-10 out of 15 chickens had low-level neutralizing antibody responses (Tables 1 and 2; Fig. 2a) . Interestingly, neutralizing antibody was detected in most chickens vaccinated with pCI-VP2 plus pCI-chIL-2 at week 2 postboosting vaccination. At week 4 postboosting, all of the chickens had an antibody response in the co-administration group, and the titer was significantly higher than that of the pCI-VP2 group ( P b 0.05) (Fig. 2a) . There was no specific IBDV antibody response detected in chickens vaccinated with pCI or pCI-chIL-2 and the unvaccinated unchallenged control groups. Fig. 2b indicates that the neutralizing antibody response induced by the pCI-VP2/4/3 DNA vaccine can be modulated by co-administration with pCI-chIL-2. Most chickens immunized with pCI-VP2/4/3 can produce neutralizing antibody, but it takes an extended amount of time to develop this response. At week 2 postprimary vaccination, the antibody levels of chickens in the pCI-VP2/4/3 group were undetectable, even when 200 Ag of DNA was used for vaccination. However, most of the chickens in the co-administration group had detectable antibody response at this time point, indicating that an antibody response can be induced earlier by co-injection with pCI-chIL-2. After boosting with pCI-VP2/4/3, most . Serum was collected weekly from 15 chickens in each group. Antibody was detected by the virus neutralization (VN) assay. The VN titer was determined by the system described by Reed and Muench (1938) . Values are shown as Geometric Mean Titer (GMT) F standard error. chickens within this group produced antibody that gradually increased in amount, indicating that a secondary immune response had been induced by the DNA vaccine. On contrast, after boosting with pCI-VP2/4/3 and pCIchIL-2, the antibody titers increased significantly ( P b 0.05). Throughout the experiment, the antibody titer of the co-administration group was significantly higher than that of the pCI-VP2/4/3 group ( P b 0.05). Chickens vaccinated with either pCI or pCI-chIL-2 and the normal control had undetectable antibody levels.
To address the possibility that DNA concentration plays a role in enhancing antibody responses, the experiment was controlled by co-delivery with backbone plasmid pCI in immunization. At week 4 postboosting vaccination, 7 out of 12 chickens had antibody responses in the pCI-VP2 group, and 6 out of 12 chickens had the antibody response in the pCI-VP2 plus pCI group (Table 3) . However, all of the chickens in the pCI-VP2 plus pCI-chIL-2 group developed antibody responses. As shown in Fig. 2c , co-delivery of the backbone plasmid does not significantly enhance the antibody response of pCI-VP2/4/3 ( P N 0.05). However, the antibody response of the group that received 200 Ag each of pCI-VP2/4/3 and pCI-chIL-2 was significantly higher than that of the group that received 200 Ag of pCI-VP2/4/3 alone ( P b 0.05). This further confirms that the enhanced antibody response is due to the co-injection of plasmid encoding chIL-2, not due to the increased amount of DNA (pCI) administrated.
Discussion
Interleukin 2 (IL-2) is a very important cytokine produced by activated T lymphocytes that exerts immunoregulatory effects on a variety of immune cells, including T cells, activated B cells, natural killer cells, and lymphokine-activated killer cells. In addition to acting as an immunoregulator, mammalian interleukin 2 (IL-2) has been shown to be a strong adjuvant for DNA vaccines (Moore et al., 2002) . The chIL-2 gene was the first cloned nonmammalian IL-2 gene and limited information is available as to the ability of chIL-2 to function as an adjuvant for avian DNA vaccines. Many immunosuppressive avian pathogens such as IBDV (Wu et al., 2000) , Marek's disease virus (Xing and Schat, 2000) , Newcastle disease virus (Thiagarajan et al., 1999) , chicken anemia virus (Markowski-Grimsrud and Schat, 2003) , and Eimeria tenella (Chio and Lillehoj, 2000) interfere with the induction of or cause abnormal production of chIL-2 in vivo. This suggests that chIL-2 may be important for control of these diseases. IBDV is a good disease model in which to study the immunoregulatory function of chIL-2, not only because it is a highly contagious immunosuppressive disease that depletes B cell populations within the bursa of Fabricius, but also because both the humoral and cell-mediated immune response are important in control of the disease. In this study, we have found that the immunogenicity of a DNA vaccine against IBDV can be improved by co-delivery of a plasmid encoding chIL-2. The potential roles of chIL-2 in the IBDV DNA vaccine include (1) enhancement of immunoprotection by IBDV DNA vaccine against both homologous and heterologous virulent strains of IBDV; (2) reduction of IBDV antigen replication in the bursa of Fabricius after virulent IBDV challenge; and (3) improvement of the specific IBDV neutralizing antibody response induced by the DNA vaccine. We also showed that the pCI-chIL-2, but not the backbone plasmid pCI, contributes to increased immunogenicity of DNA vaccine against IBDV. In addition, chIL-2 has many distinct advantages over conventional adjuvants (such as liposome, DMSO), including biological stability and safety. Our work indicates that chIL-2 is a promising cytokine adjuvant for IBDV DNA vaccines and perhaps other avian pathogen DNA vaccines in the future.
The major host-protective antigen of IBDV, VP2, contains at least three independent epitopes responsible for the induction of neutralizing antibodies. It has been shown that the ability of VP2-based subunit vaccine to protect against virulent IBDV is highly dependent on the conformation and structure of the antigenic sites. VP2 expressed in E. coli was not efficient in eliciting virusneutralizing antibody (Jagadish et al., 1988) . Denatured VP2 does not induce protection in chickens (Fahey et al., 1989) , and denatured and renatured VP2 is also unable to induce neutralizing antibodies in chickens (Ö ppling et al., 1991) . We and other researchers (Fodor et al., 1999) have shown that chickens vaccinated with a plasmid encoding the VP2 gene lack a neutralizing antibody response. Only 3 out of 15 chickens were protected from bursal damage after challenge with the homologous strain ZJ2000. None of the chickens were protected from bursal damage by the heterologous strain BC6/85 although a large amount of DNA was administered. Thus, a VP2-based DNA vaccine can only protect chickens from clinical outbreaks and mortality, but not from bursal damage. The low efficacy of the VP2-based DNA vaccine may be due to conformational defects in its epitopes and low immunogenicity. In contrast, most of the chickens vaccinated with pCI-VP2 plus pCI-chIL-2 had detectable antibody responses, and some of the chickens were protected from bursal damage by both ZJ2000 and BC6/85. One possible explanation for this result is that the expressed VP2 protein triggers a weak immune response in vivo that is not strong enough to protect against virulent IBDV infection, but can be amplified by the expression of chIL-2. Therefore, a stronger antibody response and a higher level of protection were observed when chickens were co-vaccinated with both pCI-VP2 and pCI-chIL-2.
The polyprotein precursor (VP2/4/3) is proteolytically processed to give rise to mature VP2, VP3, and VP4 polypeptides, generating the natural conformation of multi-ple immunodominant epitopes. In addition, expression of the IBDV polyprotein in cells may generate virus-like particles (VLP) in the form of close-packed paracrystalline arrays, which are very similar to authentic IBDV particles in shape and size, as previously shown by electron microscopy, and are specifically recognized by anti-IBDV antibodies (Fernández-Arias et al., 1998; Martinez-Torrecuadrada et al., 2003) . Therefore, it is not surprising that the immunogenic response induced by the plasmid encoding the polyprotein was much higher than that induced by the plasmid encoding the VP2 gene of IBDV. Our data indicates that the plasmid encoding the polyprotein gene provides good protection against the homologous strain ZJ2000 (Table 1 ), but not against the heterologous strain BC6/85 (Table 2) . Most importantly, co-administration of 200 Ag each of pCI-VP2/ 4/3 and pCI-chIL-2 provides complete protection against the homologous virulent ZJ2000 strain (Table 1) and enhances protection against the heterologous virulent BC6/85 strain ( Table 2 ). In accordance with the experimental challenge assay, the antibody response induced by co-administration of pCI-VP2/4/3 plus pCI-chIL-2 was significantly higher than that induced by vaccination with pCI-VP2/4/3 alone ( P b 0.05). Also, the production of antibody induced by coadministration of the plasmids began 1-2 weeks earlier than when pCI-VP2/4/3 was administrated alone. Namely, the antibody silent period becomes shorter when chIL-2 is used as an adjuvant. This could be very helpful in the control of infection soon after chickens are exposed to IBDV.
To address whether the DNA concentration affects the efficacy of DNA vaccine, chickens were vaccinated with equal amounts of DNA by co-injection with either the empty backbone plasmid pCI or pCI-chIL-2. The results showed that the backbone plasmid pCI does not significantly enhance the efficacy of either the VP2 or VP2/4/3-based DNA vaccines ( P N 0.05) ( Table 3) . In contrast, co-injection with pCI-chIL-2 significantly enhances immunoprotection and the antibody response ( P b 0.05) (Tables 1-3) . Therefore, the increased efficacy is indeed due to the use of pCI-chIL-2, but not the extra DNA of the pCI vector itself. It is well known that CpG oligodeoxynucleotide (ODN) can enhance the immunogenicity of DNA vaccines (Rankin et al., 2001 ). However, no evidence has shown that the backbone plasmid pCI vector can directly function as a CpG ODN. A recent study has shown that efficacy of DNA vaccines against IBDV was enhanced by co-administration with CpG ODN (Wang et al., 2003) . The CpG ODNs were synthesized artificially and composed of a 20-30-bp nucleotide sequence containing potential stimulatory motifs, similar to those widely used in other studies investigating the adjuvant effect of CpG (Rankin et al., 2001) .
Recent studies have shown that recombinant chIL-2 has functions similar to those of mammalian IL-2 (Kaiser and Mariani, 1999; Stepaniak et al., 1999) . IL-2 is known to promote a Th1-type response (Chow et al., 1998) and may be most useful as a vaccine adjuvant in diseases where cell-mediated immunity plays an important role in protection against pathogens. Although the humoral immune response is important for protecting chickens against IBDV infection, there is increasing evidence that the cellular immune response is also critical. In this study, we have demonstrated that vaccination with pCI-VP2 is able to protect chickens from clinical outbreaks and mortality caused by challenge with either the ZJ2000 or BC6/85 strain of IBDV. Additionally, it induced protection against bursal damage caused by the ZJ2000 strain although half of the immunized chickens lacked an antibody response. Furthermore, Yeh et al. (2002) found that cell-mediated immunity alone can protect birds against virulent IBDV in the absence of antibody. Similarly, it has been reported that recombinant fowlpox VP2 vaccine induced protection in the absence of detectable serum antibodies (Shaw and Davison, 2000) . In addition, we found that complete protection is obtained when pCI-chIL-2 is used as an adjuvant. Rautenschlein et al. (2002a Rautenschlein et al. ( , 2002b demonstrated that T cells were necessary to achieve full protection against virulent IBDV. Thus, co-administration of pCI-VP2/4/3 and pCIchIL-2 possibly induces a T cell response that results in a full protection. Co-administration of pCI-VP2 plus pCIchIL-2 provides the same level of bursal protection against strain ZJ2000 (Table 1) and even better bursal protection against BC6/85 (Table 2 ) than administration of pCI-VP2/4/3 alone. However, the antibody titer of the pCI-VP2 plus pCI-chIL-2 group was much lower than that of the pCI-VP2/4/3 group (Figs. 2a and b) . The lack of correlation between protection and antibody further supports the possibility that a cell-mediated immune response is involved in protection against IBDV. In addition, it has been reported that subcutaneous injection of chickens with a plasmid expressing IL-2 enhances T cell and natural killer cell responses (Chio and Lillehoj, 2000) . ChIL-2 also directly induces activation and proliferation of chicken T cells in vivo (Hilton et al., 2002) . Overall, the above observations strongly indicate that chIL-2 can enhance not only the humoral immune response, but also the cell-mediated response triggered by DNA vaccination.
Other functions of chIL-2 may also play a role in enhancing the immunogenicity of IBDV DNA vaccines. Recently, recombinant chIL-2 has been found to significantly increase the phagocytosis and bactericidal activity of heterophils, which are the avian equivalent of neutrophils and function as professional phagocytes to aid in regulation of innate host defenses (Kogut et al., 2002) . ChIL-2 also enhances respiratory burst in response to antigen stimulation (Kogut et al., 2002) . This indicates that chIL-2 may be very important for disease prevention and resistance to pathogen infections. It is also possible that chIL-2 may have other potential functions such as immunotherapy, which has been well documented in mammalian IL-2. During the IBDV challenge test, we also found that chickens vaccinated with pCI-chIL-2 had slightly less severe bursal damage than those vaccinated with pCI or unvaccinated but challenged controls. The adjuvant activity of chIL-2 may be also involved in promoting the avian immune system to produce other cytokines such as chicken IFN-a and IFN-g, which also function as immunoenhancers. It has been shown that co-administration of antigen and IFN-g enhances antibody responses in chickens and co-injection of the IFN-g gene with an Eimeria DNA vaccine improves protective immunity against coccidiosis (Min et al., 2001) .
Recently, antigenic variant and very virulent (vvIBDV) of IBDV have emerged and caused considerable economic losses to the poultry industry around the world (Darteil et al., 1995; Ismail et al., 1990; Tsukamoto et al., 1999; Yu et al., 2000 Yu et al., , 2001 . Traditional inactivated or attenuated vaccines cannot provide sufficient protection against these variants and vvIBDV (Tsukamoto et al., 2000; Yeh et al., 2002; Yu et al., 2000) . In an experimental challenge assay, it was shown that the protection of IBDV vaccine against virulent IBDV was highly dependent on the antigenic correlation value between vaccinated virus and challenge virus (Shaw and Davison, 2000) . DNA vaccination may overcome these defects because it is able to induce both humoral and cell-mediated immunity. Although the antigenic correlation value between IBDV strains ZJ2000 and BC6/85 is unknown at molecular level, the strain ZJ2000 polyprotein gene-based DNA vaccine provided strong protection against BC6/85, indicating that cross-protection was induced by DNA vaccination. Our preliminary data also indicates that co-expression of the polyprotein of IBDV and chIL-2 provides protection against virulent IBDV strain ZJ991, which is an antigenic variant strain isolated in China (our unpublished data). These observations suggest that co-administration of DNA vaccines and chIL-2 could potentially be used as a standard vaccination method.
In conclusion, chIL-2 is a strong immunoregulator of the IBDV DNA vaccine. It enhances the IBDV-specific antibody response and provides protection against challenge with homologous and heterologous virulent IBDV. Further research is needed to test chIL-2 as an adjuvant for use with DNA vaccination against antigenic variant IBDV and vvIBDV. In addition, it will be necessary to determine if chIL-2 has similar adjuvant functions when co-administered with other avian viral DNA vaccines.
Materials and methods
Animals
The Xiaoshan chicken is a local Chinese breed that was purchased from Xiaoshan Chicken Farm, Xiaoshan, Zhejiang, P.R. China. Specific pathogen-free (SPF) eggs and chickens were purchased from the Experimental SPF Chicken Farm, Shandong Institute of Poultry Science, Shandong, P.R. China. Chickens were hatched and raised in a disease containment building, and then moved into isolators before inoculation. The flexible plastic isolators were supplied with filtered intake and exhaust air.
Virus
ZJ2000 is a virulent IBDV strain that was originally isolated from a commercial layer flock in Hangzhou, Zhejiang, P.R. China. This virus strain was adapted in chicken embryo fibroblasts (CEFs) and used for the virusserum neutralization test. BC6/85, another virulent IBDV strain, was used for the virus challenge studies and was purchased from China National Institute for Supervision of Veterinary Pharmaceuticals, Beijing, P.R. China. Both ZJ2000 and BC6/85 are highly virulent, causing severe bursal lesions characterized by inflammation, edema, and point bleeding at day 4 postchallenge.
Construction of DNA vaccine expression plasmids
Construction of the IBDV-ZJ2000 VP2 and VP2/4/3 recombinant pCI (Promega) expression plasmids has been described previously (Li et al., 2003) . The VP2/4/3 was released from the pGEM-T-Easy vector by EcoRI and KpnI digestion and ligated into the pCI vector cut by the same enzymes, resulting in construction of the pCI-VP2/4/3 plasmid. The VP2 was released from pGEM-T-Easy vector by EcoRI and XbaI digestion and ligated into pCI at the same sites, resulting in construction of the pCI-VP2 plasmid. Large-scale extraction and purification of the plasmids were performed as previously described (Li et al., 2003) .
Cloning and identification of chicken interleukin 2 cDNA
Spleens from 4-week-old Xiaoshan chickens were collected aseptically into RPMI 1640 medium (Invitrogen). Spleen tissue was minced using a pair of scissors and passed through a steel mesh to obtain a homogeneous cell suspension. The cells were pelleted by centrifugation at 1000 Â g for 20 min at 4 8C and washed twice in RPMI 1640 medium. After assessment of cell viability by Trypan blue dye exclusion technique, the cells were resuspended at a concentration of 10 7 cells/ml in RPMI 1640 medium (containing 1% l-glutamine, 2 mg/ml bovine serum albumin, 1 U/ml penicillin, and 1 Ag/ml streptomycin). The cells were cultured in six-well plates and stimulated with ConA at a final concentration of 10 Ag/ml at 40 8C in a humidified atmosphere with 5% CO 2 . The cells were harvested, and the mRNA was isolated by Trizol reagent (Invitrogen) at 6, 12, 18, and 24 h after ConA stimulation.
To obtain the full coding sequence of chIL-2, primer P1 (5V -ATGATGTGCAAAGTACTGATC-3V ) and primer P2 (5V -TTATTTTTGCAGATATCTCACAAAG-3V ) were designed based on the sequence of chIL-2 published by Sundick and Gill-Dixon (1997) . First-strand cDNA synthesis was performed for 90 min at 42 8C in a 20 Al volume containing 5 pmol of primer P2, 200 U Superscript II (Invitrogen), and 500 ng mRNA. The cDNA fragment was amplified using the Expand High Fidelity PCR System (Roche Diagnostics, Indianapolis, IN). The optimal reaction mixture contained 2 Al of template, 5 Al of 1 Â Expand High Fidelity PCR buffer, 50 AM of each dNTP, 0.5 pM of each primer, and 2.5 mM MgCl 2 . The amplification program included 4 min at 94 8C for predenaturation, followed by 30 cycles of 45 s at 94 8C for denaturation, 45 s at 55 8C for annealing, 1 min at 72 8C for elongation, and finally a single 3-min incubation at 72 8C for prolonged elongation. The desired 737-bp fragment was cloned into the pGEM-T Easy Vector by the T-A cloning kit (Promega). Finally, the 432-bp fragment containing the whole chIL-2 ORF was amplified by PCR with primers P3 (5V CGGAATTCATGATGTGCAA-AGTACTGATC 3V ) and P4 (5V TTGTCGACTTACACCA-CCACCACCACCACTTTTTGCAGATATCTCACAAA 3V ), digested with EcoRI and SalI, and cloned into the pCI vector at the same sites, resulting in the construction of the pCI-chIL-2 plasmid. The correct orientation of the insert was verified by enzyme digestion and sequencing.
Animal immunization and experimental challenges
Experiment 1: challenge with homologous IBDV virulent strain ZJ2000
Fourteen-day-old SPF chickens were randomly divided into eight groups with 15 chickens per group. Chickens in group 1 received 200 Ag of pCI-VP2. Group 2 received 200 Ag each of pCI-VP2 and pCI-chIL-2. Group 3 received 200 Ag of pCI-VP2/4/3. Group 4 received 200 Ag each of pCI-VP2/4/3 and pCI-chIL-2. Group 5 received 200 Ag of pCI-chIL-2. Group 6 received 200 Ag of pCI. Group 7 served as the unvaccinated challenge control (challenge control), and Group 8 served as the unvaccinated yet unchallenged control (normal control). All of the chickens were immunized intramuscularly at 14 days of age. After 2 weeks, the chickens were boosted with DNA vaccines using the same route and dosage. At week 4 postboost, 15 chickens from each group were challenged with homologous virulent IBDV strain ZJ2000. The chickens were observed every 6 h to determine if any clinical signs of IBDV emerged and to remove the dead chickens from the isolators. All of the chickens challenged with IBDV were euthanized at 4 days postchallenge. Bursas and spleens were removed and weighed, and the mean organ/body weight (BW) ratio was determined according to Ismail et al. (1990) using the following formula: (organ weight in grams Â 1000)/BW in grams. The protection rate for each challenge group was initially calculated based on gross bursal lesions and further confirmed by bursa histopathological examination. Chickens with complete absence of histological lesions were considered to be protected against IBDV challenge. Thin sections of bursa were also subjected to an immunofluorescence assay for antigen detection.
Experiment 2: challenge with heterologous virulent BC6/85
The experimental design, DNA vaccination, virus challenge, and evaluation of protection procedures were identical to those used in experiment 1 except that the challenge virus was changed to the virulent IBDV strain BC6/85. Group 10 served as the challenge control, and Group 11 served as the normal control. The vaccination procedure was the same as that used in experiment 1. At week 4 postboosting, 12 chickens from each group were challenged with BC6/85. The protection ratio was evaluated as described in experiment 1.
Virus neutralization assay for virus-specific antibodies
Blood samples were taken from 15 chickens selected randomly from each group at 1-week intervals after immunization. Serum samples were prepared, inactivated for 30 min at 56 8C, and stored at À20 8C. The virus neutralization (VN) assay was carried out by varying the serum levels with a constant virus concentration on primary SPF CEFs as previously described (Tsai and Saif, 1992) . Briefly, serial 2-fold dilutions of each serum sample were prepared in MEM, neutralized with 100 TCID 50 of the IBDV strain ZJ2000, and transferred onto monolayers of CEFs cultured in 96-well plates. The VN titer was determined from the cytopathological effect (CPE) using the system described by Reed and Muench (1938) . The geometric mean titer (GMT) of antibody was calculated for each group.
Antigen detection of bursa of Fabricius
The immunofluorescence assay was used to determine the presence of IBDV antigens in the bursa of Fabricius after virus challenge. Each bursa was frozen and then sectioned in a cryostat at 6-mm thickness. The sections were fixed in acetone/methanol (1:1) for 5 min at room temperature, stained with anti-IBDV chicken hyperimmune serum, and then stained with a goat anti-mouse FITC-labeled IgG (Invitrogen). The sections were examined with a fluorescent microscope. Bursa sections completely absent of fluorescence were considered negative.
Histopathological examination of bursal samples
All of the bursal samples were fixed in 10% formaldehyde and embedded with wax. Thin sections were prepared for hematoxylin-eosin (HE) staining and histopathological examination of bursal lesions. The lesions on bursa of Fabricius were scored using the system developed by Shaw and Davison (2000) with the following modification: score 0-no bursal damage or lesions in any follicle, clear demarcation of medulla and cortex; score 1-mild necrosis and mild lymphocyte depletion of a few follicles with the overall bursal architecture maintained; score 2-moderate atrophy or lymphocyte depletion in 1/3 to 1/2 of the follicles, aggregation of heterophils, macrophages, and hyperplasia of epithelial reticular cells with some vacuolelike structures; score 3-more than 1/2 of follicles with severe necrosis, atrophy, and lymphocyte depletion, and loss of the outline of follicular architecture such that it is replaced by proliferated connective tissue and fibroplasias. Bursal lesion score of each group was shown as the mean F standard deviation.
Statistical analysis
The average organ/body weight ratios of the challenged groups were compared with those of the control groups for statistical significance using analysis of variance followed by Fisher's least significance difference. Antibody titers and bursal lesion scores were analyzed using the SPSS 8.0 software (SPSS Inc. Chicago, IL, USA) to determine the differences among groups.
